Moleculin to Participate in the Virtual Investor Lunch Break Series
Moleculin to Participate in the Virtual Investor Lunch Break Series
Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Wednesday, June 12th at 12:00 PM ET
2024年6月12日星期三，莫勒克林生物技術公司的董事長兼首席執行官沃爾特•克萊普將在現場直播中發言。th東部時間下午12:00
HOUSTON, June 5, 2024 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Wednesday, June 12, 2024 at 12:00 PM ET.
2024年6月5日，休斯頓——莫勒克林生物技術公司（納斯達克股票代碼：MBRX）是一家臨床階段的藥品公司，擁有面向難治性腫瘤和病毒的廣泛藥物組合，並於今天宣佈將在《虛擬投資者午餐休息：莫勒克林機會》活動上發言。莫勒克林機遇：虛擬投資者午餐休息該活動將於2024年6月12日星期三上午12:00（東部時間）舉行。
As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview and business outlook. In addition to the prepared remarks, interested parties will have the opportunity to submit questions live during the event. Mr. Klemp will answer as many questions as possible in the time allowed.
作爲活動的一部分，莫勒克林公司的董事長和首席執行官沃爾特•克萊普將提供公司概述和業務前景。除了準備好的發言外，有興趣的人可以在活動期間在線提交問題。克萊普先生將在允許的時間內回答儘可能多的問題。
A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.
機器人演示的網絡直播視頻將在公司網站（aimimmuno.com）的“活動”頁面上提供。演示的網絡直播視頻將在現場演示後兩小時提供，並可訪問90天。本次活動的直播將在公司網站的活動頁面下提供。的信息，請訪問aimimmuno.com並與公司聯繫。所有板塊投資者，詳見公司網站（moleculin.com）。現場活動結束兩小時後，將提供網絡直播回放，並可供觀看90天。
About Moleculin Biotech, Inc.
關於莫勒克林生物技術公司Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms and to eliminate the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data related to its active clinical trials are subject to change.
莫勒克林生物技術公司是一家臨床階段的藥品公司，擁有一個不斷增長的藥物組合，包括第二階段臨床試驗計劃，用於難治性腫瘤和病毒。公司的領先項目安納黴素是一種下一代蒽環類藥物，旨在避免多藥耐藥機制，並消除目前處方蒽環類藥物常見的心臟毒性。安納黴素目前正在開發用於治療復發或難治性急性髓細胞白血病（AML）和軟組織肉瘤（STS）肺轉移病例。與正在進行的臨床試驗相關的所有中期和初步數據都可能會發生變化。
Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as certain cancer indications.
此外，公司正在開發WP1066——一種能夠抑制p-STAT3和其他致癌轉錄因子並同時刺激自然免疫反應的免疫/轉錄調節劑，用於治療腦腫瘤、胰腺癌和其他癌症。莫勒克林還致力於開發一系列抗代謝物，包括WP1122，用於潛在的病毒治療，以及某些癌症適應症。
For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.
有關該公司的更多信息，請訪問其官網www.moleculin.com，並關注推特, LinkedIn和頁面。Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
投資者聯繫人：
JTC團隊有限責任公司
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-lunch-break-series-302163997.html
查看下載多媒體原始內容：資訊來源：Moleculin將參加虛擬投資者午餐會系列活動。
SOURCE Moleculin Biotech, Inc.
資訊來源：Moleculin生物科技公司。